River Wealth Advisors LLC Grows Position in Cencora, Inc. $COR

River Wealth Advisors LLC boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 6.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,905 shares of the company’s stock after purchasing an additional 2,573 shares during the period. Cencora makes up approximately 1.6% of River Wealth Advisors LLC’s portfolio, making the stock its 17th biggest holding. River Wealth Advisors LLC’s holdings in Cencora were worth $13,409,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Cornerstone Wealth Group LLC increased its holdings in shares of Cencora by 1.3% during the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after buying an additional 30 shares during the last quarter. Security Financial Services INC. boosted its holdings in Cencora by 2.6% in the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after acquiring an additional 33 shares during the last quarter. Hemington Wealth Management grew its position in Cencora by 12.0% during the third quarter. Hemington Wealth Management now owns 327 shares of the company’s stock valued at $102,000 after acquiring an additional 35 shares during the period. Quadcap Wealth Management LLC increased its stake in Cencora by 1.5% during the second quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock worth $722,000 after acquiring an additional 36 shares during the last quarter. Finally, Howard Capital Management Inc. increased its stake in Cencora by 2.5% during the third quarter. Howard Capital Management Inc. now owns 1,499 shares of the company’s stock worth $468,000 after acquiring an additional 37 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on COR. Evercore decreased their target price on Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Robert W. Baird set a $415.00 price objective on shares of Cencora in a research note on Tuesday, January 13th. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Finally, UBS Group lifted their target price on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $399.00.

Insider Transactions at Cencora

In other news, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 15,220 shares of company stock valued at $5,282,867. 0.38% of the stock is currently owned by insiders.

Cencora Stock Up 1.4%

Shares of NYSE:COR opened at $371.86 on Friday. The company has a market capitalization of $72.34 billion, a price-to-earnings ratio of 44.69, a price-to-earnings-growth ratio of 1.73 and a beta of 0.68. The company has a 50 day moving average of $351.72 and a two-hundred day moving average of $333.89. Cencora, Inc. has a 52-week low of $248.59 and a 52-week high of $377.54. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. The business had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.73 earnings per share. As a group, analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be paid a dividend of $0.60 per share. The ex-dividend date is Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.6%. Cencora’s dividend payout ratio (DPR) is currently 28.85%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.